Tranzactioneaza Vaccinex (US.VCNX) - 7.3 USD (%) Tranzactioneaza
Indici
Descriere companie
Vaccinex Inc. (http://www.vaccinex.com/) is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate, pepinemab (VX15/2503), is a humanized monoclonal antibody that binds and blocks the signaling activity of SEMA4D. The Company’s pipeline products include pepinemab COMBO with avelumab in NSCLC, is completed Phase II clinical trial; pepinemab COMBO with pembrolizumab in first-line R/M HNSCC, is in Phase II clinical trial; pepinemab in huntington’s Disease, is completed Phase II clinical trial; pepinemab in Alzheimer’s Disease, is in Phase II clinical tial; Ab Discovery, Target ID, Complex Membrane Protein expression; VXS (Anti-CXCL13) for Autoimmune Disease and Cancer, is in Phase I clinical trial.